AML

SIERRA Trial Delivers Initial Data for Older Patients With AML

May 01, 2020

Rajneesh Nath, MD, discusses the early results of the phase III SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia.

FDA Grants Priority Review to Oral Hypomethylating Agent for Frontline Maintenance in AML

May 01, 2020

"The acceptance of our submission for CC-486 represents an important step towards a potential new maintenance treatment to address an urgent medical need for patients with AML and we look forward to working with the FDA during its review of CC-486."

Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial

April 08, 2020

Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.

AML Trial Halted Due to COVID-19 Pandemic

March 30, 2020

A phase II trial of ficlatuzumab, an investigational HGF inhibitory antibody, in patients with relapsed and refractory acute myeloid leukemia joins the growing list of clinical trials halted due to the coronavirus disease 2019 pandemic.

Venetoclax Combination Improves OS in Acute Myeloid Leukemia

March 23, 2020

Venetoclax in combination with azacytidine demonstrated a statistically significant improvement in overall survival and achieved a satisfactory composite complete remission rate in previously untreated patients with acute myeloid leukemia, meeting the co-primary end points of the phase III VIALE-A study. Genentech, the developer of venetoclax, announced the positive news in a press release, also noting that safety profiles of both drugs were consistent with prior reports.

Clinical Researchers Establish Risk Score for Heart Failure in Patients With AML

March 16, 2020

Researchers have developed a baseline score to determine the risk for heart failure in patients with acute leukemias, to address the scarcity in knowledge around the increasing incidence and risk factors of symptomatic heart failure in this patient population. The findings were published in JACC: CardioOncology.

Deciding the Next Steps for Treating Patients With Acute Myeloid Leukemia

March 13, 2020

Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.

86% Remission Rate Observed in Chemotherapy and ARC Combination in Relapsed/Refractory AML

March 11, 2020

After demonstrating promising results that were comparable to targeted therapies in the first 2 cohorts of a phase I clinical trial, the combination of cladribine, cytarabine, granulocyte-colony stimulating factor, and mitoxantrone plus the antibody radiation conjugate lintuzumab-Ac225 in patients with relapsed/refractory acute myeloid leukemia is now being explored in a third cohort.

Venetoclax Plus Low-Dose Cytarabine Fails to Improve OS in AML

March 03, 2020

The combination of venetoclax plus low-dose cytarabine did not demonstrate a statistically significant improvement in overall survival compared with LDAC plus placebo in patients with acute myeloid leukemia who were ineligible for intensive chemotherapy at the time of a planned analysis, missing the primary end point of the phase III VIALE-C trial.

SIERRA Trial: Background on the Iomab-B Combination in Relapsed/Refractory AML

February 19, 2020

In an interview with Targeted Oncology, Rajneesh Nath, MD, discussed the background and rationale for the phase III SIERRA trial. He also explained what this research means for the treatment landscape of acute myeloid leukemia.